We are less than a month away from the most important interventional cardiology event in Latin America. Consequently, we have started to share information on some of the most appealing sessions that you will be able to enjoy in Mexico City from August 1st to 3rd, 2018. On that vein, we are pleased to communicate<a href="https://solaci.org/en/2018/07/03/over-10-keynote-conferences-confirmed-at-solaci-socime-2018-congress/" title="Read more" >...</a>
Is it possible for a soccer match to trigger an infarction? Is it possible for the stress derived from watching our national team play to trigger a cardiovascular event? Many might think that these are exaggerations. However, not only is it possible, but it has been proved beyond the shadow of a doubt for some<a href="https://solaci.org/en/2018/06/28/cardiovascular-events-during-world-cup-soccer-an-old-article-worth-remembering/" title="Read more" >...</a>
In the daily practice and in randomized studies such as Syntax or Freedom, most cardiovascular surgeons across the world use angiography guided CABG to teat 50% coronary stenosis. Many of these lesions might not be functionally significant. There is abundant evidence in favor of fractional flow reserve (FFR) guided PCI, but FFR guided CABG is<a href="https://solaci.org/en/2018/06/27/ffr-vs-angiography-guided-cabg/" title="Read more" >...</a>
Transcatheter aortic valve replacement (TAVR) using the ACURATE neo device depends, largely, on correct patient selection and appropriate oversizing. The individual anatomy of each patient, namely periannular and aortic root calcification, must be taken into account. The ACURATE neo valve (Symetis/Boston, Ecublens, Switzerland) is a new-generation self-expanding valve characterized by a stent design shaped as an X<a href="https://solaci.org/en/2018/06/15/the-largest-registry-on-the-acurate-neo-valve/" title="Read more" >...</a>
Almost 80% of all patients randomized in this study reported Canadian Cardiovascular Society class II or III angina, and almost all of them (97%) had more than 1 positive non-invasive ischemia test that matched the area of their single diseased coronary vessel. Beyond fractional flow reserve (FFR) or instantaneous wave-free ratio (iFR), the study randomized patients to<a href="https://solaci.org/en/2018/06/11/angina-is-as-subjective-as-any-other-pain/" title="Read more" >...</a>
Courtesy of Dr. Carlos Fava. The presence of CTO hovers around 15, 20% in coronary angiographies of patients with chronic stable angina, but only 5% receive percutaneous coronary intervention (PCI). One of the obstacles to percutaneous revascularization is the lack of relevant studies justifying it, though we do have different comparative studies that improve symptoms, ventricular<a href="https://solaci.org/en/2018/06/08/cto-revascularization-improves-quality-of-life/" title="Read more" >...</a>
A new edition of EuroPCR has come and gone. Now is the time to make a balance and review the main presentations at one of the most important European congresses on cardiovascular interventions. Thus, we have selected the six most relevant studies presented at the event. In our opinion, you cannot afford to miss them!<a href="https://solaci.org/en/2018/06/07/europcr-2018-highlights-the-best-of-a-congress-that-left-plenty-of-news/" title="Read more" >...</a>
Courtesy of Dr. Alejandro Lakowsky, MTSAC (Full Member of the Argentine Society of Cardiology) The New England Journal of Medicine (NEJM) recently published an article about the POINT trial (simultaneously presented at the European Stroke Organisation Conference), a long-awaited randomized clinical trial to assess the efficacy and safety of dual antiplatelet therapy (DAPT) with aspirin<a href="https://solaci.org/en/2018/06/06/what-antiplatelet-therapy-should-we-use-in-patients-with-stroke-tia-interesting-results-for-the-point-trial/" title="Read more" >...</a>
This work compared the safety and efficacy of angioplasty with thin-strut (80 µm) sirolimus-eluting stents with a cobalt chromium structure (Ultimaster) vs. thick-strut (120 µm) biolimus-eluting stents with a cobalt chromium structure (Nobori). This study compared two prospective multicenter single-arm registries: e-Ultimaster and NOBORI 2. The Ultimaster Registry included over 37,000 patients in 4 continents, while the NOBORI 2 Registry included<a href="https://solaci.org/en/2018/05/31/europcr-2018-ultimaster-registry-difference-in-strut-thickness/" title="Read more" >...</a>
The index of microcirculatory resistance might guide therapy and controlled intermittent coronary sinus occlusions, improve microvascular function, and reduce infarct size. This study included patients with prior ST-segment elevation myocardial infarction treated with primary angioplasty. Researchers measured the index of microcirculatory resistance before stenting and intermittent coronary sinus occlusion was used if the result was<a href="https://solaci.org/en/2018/05/31/europcr-2018-oxami-picso-coronary-sinus-occlusion-improving-microvascular-function-and-reducing-infarct-size/" title="Read more" >...</a>